Evidence map›Paper›PMID 40017515›Full record

ArticleFrontiers in cardiovascular medicine2025

Network pharmacology to unveil the blood components and mechanisms of Tongmai Yangxin Pills in treating elderly coronary heart disease.

Yue Zhang, Chao-Hui Li, Yi-Zhi Yan, Jie-Yun Lin, Shan-Shan Zhu, Si-Jie Tan, Peng Zeng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yue Zhang *Department of Histology and Embryology, School of Basic Medicine, Hengyang Medical School, University of South China, Hengyang, China.
Chao-Hui Li *Logistics Service Center Medical Office, University of South China, Hengyang, China.
Yi-Zhi YanDepartment of Histology and Embryology, School of Basic Medicine, Hengyang Medical School, University of South China, Hengyang, China.
Jie-Yun LinDepartment of Histology and Embryology, School of Basic Medicine, Hengyang Medical School, University of South China, Hengyang, China.
Shan-Shan ZhuDepartment of Histology and Embryology, School of Basic Medicine, Hengyang Medical School, University of South China, Hengyang, China.
Si-Jie TanDepartment of Histology and Embryology, School of Basic Medicine, Hengyang Medical School, University of South China, Hengyang, China.
Peng ZengDepartment of Histology and Embryology, School of Basic Medicine, Hengyang Medical School, University of South China, Hengyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Tongmai Yangxin Pills (TMYXP) is a well-known traditional Chinese medicine compound to treat coronary heart disease (CHD). Aging is a key immutable independent risk factor for CHD. Currently, there are few gene expression profiles of patients treated with traditional Chinese medicine (TCM) or TCM compound. However, the chemical composition and underlying mechanisms of TMYXP against elderly CHD need to be elucidated. Objective: Exploring the mechanism of TMYXP in treating elderly CHD based on human gene expression profiles, and find the key pharmacodynamic ingredients of TMYXP in treating elderly CHD based on plasma pharmacochemistry and network pharmacology. Methods: A strength of this study is the use of network pharmacology analysis of gene expression profiles in elderly CHD patients before and after TMYXP treatment. This study focused on peripheral blood mononuclear cell samples from 6 elderly patients with CHD over 60 years old (GSE142008). A total of 40 blood components of TMYXP identified by UPLC/Q-TOF-MS method in the plasma of SD rats. Then, we collected literature-validated TMYXP blood component targets for further network pharmacology analysis. Results: All blood components of TMYXP exhibited non-toxic properties. By retrieving validated TMYXP blood components's targets, 15 blood components correspond to a total of 4,789 targets. Genistein, emodin, isoliquiritigenin, glycyrrhizic acid, gallic acid, verbascoside, calycosin, rhein, formononetin and ephedrine were the most potential anti-CHD blood components in TMYXP. The above 10 key blood components of TMYXP mainly regulate hub genes Conclusion: This study builds a bridge connecting TMYXP blood components and its confirmed clinical efficacy, identifies a series of anti-CHD lead compounds, and analyzes their possible mechanisms for treating CHD. The research strategy of this study has the potential to promote the modernization and transformation of TCM and promote the drug development.

Indexed as

blood componentscoronary heart diseasemechanismnetwork pharmacologyplasma pharmacochemistryTongmai Yangxin pills

Identifiers

PMID40017515
PMCPMC11865046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.